The History Behind The Drug-Device Combos Targeted By FTC

 
• By Brenda Sandburg
Inhalers
Inhalers whose patents were deemed improperly listed in the Orange Book by the Federal Trade Commission have retained market dominance with their device components. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics